Paxil May Pose Increased Risk of Birth Defects, GSK Says

Drug Industry Daily
KEYWORDS FDA / labeling

A new epidemiologic study of GlaxoSmithKline’s (GSK) top-selling antidepressant Paxil suggests the drug may be associated with an increased risk of birth defects compared to other antidepressants, GSK states in a recently issued “Dear Healthcare Professional” letter.

To View This Article:


Subscribe To Drug Industry Daily